This year‘s San Antonio Breast Cancer Symposium (SABCS) picked four poster for presentation from German Breast Group
We are delighted that our GeparNuevo (GBG 89) trial is going to be presented by Hanna Hübner as Poster Spotlight Discussion:
Title: “Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial”.
Session: (PS14) Poster Spotlight Session 14: Setting Expectations for Toxicities Related to I/O Therapy (5:30 PM – 6:30 PM); Thursday, December 7, 2023
6:06 PM – 6:10 PM Room: Hemisfair Ballroom 1-2
GeparX (GBG 88)
Title: “Germline mutation status of BRCA1/2 (Breast cancer gene 1 and 2) and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA)”. Rita Schmutzler et. al
GeparTrio (GBG 24), GeparQuattro (GBG 40), GeparQuinto (GBG 44)
Title: “CDH1 (Cadherin1) mutations predict resistance to neoadjuvant taxane therapy”. Stian Knappskog et. al
PenelopeB (GBG 78)
Title: “Overall survival and disease recurrence rates in patients with invasive lobular breast cancer of the PenelopeB cohort”. Hervé Bonnefoi et. al
KATHERINE
General Session 3 (GS3-012) Oral presentation (8:15 AM – 11:15 AM); Friday, December 8, 2023; 11:00 AM – 11:15 AM (18:00 – 18:15 CET); Room: Hall 1
Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis
Presented by Sibylle Loibl
